MedWatch

Danish biotech company receives millions from US based capital fund

A new Danish biotech company has secured millions in a funding round led by the reputable US based capital fund Sofinnova Ventures, joined by Novo Seeds and Lundbeck Fond Emerge. Now, it goes for phase II and an initial public offering (IPO).

Foto: Colourbox

In Denmark, securing even modest funding for development activities can be hard for a new, ambitious biotech company – even if it has a good idea.

Thus, the news about a small company receiving USD 17.7 million from an investor consortium might seem like overkill. Nevertheless, this is the case of the three years old biotech company Dermtreat. The biggest and most remarkable investor is the US-based venture company Sofinnova, managing billions of dollars.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier